CONTEXT: RWE study presented at ASCO Gastrointestinal Cancers Symposium showed first line mono therapy effective in hepatocellular carcinoma in the US.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 8
1. “First-line lenvatinib monotherapy is effective for unresectable hepatocellular carcinoma (HCC) in US clinical practice, according to results from a real-world study presented at the virtual 2021 ASCO Gastrointestinal Cancers Symposium.”
2. ““In the [US] lenvatinib monotherapy was approved in August 2018 for first-line treatment of patients with unresectable [HCC] based on the pivotal trial, REFLECT,” wrote Amit G Singal, MD, University of Texas Southwestern, Dallas, and colleagues.”
3. “This study aimed to assess real-world clinical characteristics and effectiveness of lenvatinib among patients with HCC treated in US clinical practices.”
4. ““Results from this retrospective real-world study in an US population affirm the clinical effectiveness of [first-line] lenvatinib monotherapy among patients with [unresectable] HCC,” Dr Singal and colleagues concluded.”
5. “Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients treated in United States clinical practices.”
Source URL: https://www.journalofclinicalpathways.com/news/lenvatinib-effective-unresectable-hcc-real-world-setting